Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) insider transactions

In the twelve months to 10 November 2026, executives and directors of Karyopharm Therapeutics reported 21 open-market sales of 43,016 shares ($351,422) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Karyopharm Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
16 October 2026Abate KristinChief Accounting OfficerOpen-market sale−4,788$0.3418,616Form 4
1 October 2026Abate KristinChief Accounting OfficerOpen-market sale−378$1.1923,404Form 4
1 September 2026Abate KristinChief Accounting OfficerOpen-market sale−19$2.0223,782Form 4
28 July 2026Poulton StuartEVP, Chief Development OfficerOpen-market sale−189$7.1094,632Form 4
21 May 2026Bohlin Garen GDirectorGrant or award+15,508—18,517Form 4
21 May 2026Pakianathan DeepikaDirectorGrant or award+15,508—15,508Form 4
21 May 2026Greene Barry EDirectorGrant or award+15,508—16,415Form 4
21 May 2026Schor ChenDirectorGrant or award+15,508—15,508Form 4
21 May 2026Oliger Christy J.DirectorGrant or award+15,508—15,508Form 4
21 May 2026Su ZhenDirectorGrant or award+15,508—15,508Form 4
14 May 2026Mano MichaelEVP, CLO&SecretaryOpen-market sale−266$9.5094,398Form 4
14 May 2026Paulson Richard A.President and CEOOpen-market sale−2,203$9.50269,747Form 4
14 May 2026Abate KristinChief Accounting OfficerOpen-market sale−53$9.5023,801Form 4
14 May 2026Cheng Sohanya RoshanEVP & Chief Commercial OfficerOpen-market sale−324$9.50107,940Form 4
14 May 2026Rangwala ReshmaEVP & Chief Medical OfficerOpen-market sale−408$9.5056,829Form 4
14 May 2026Poulton StuartEVP, Chief Development OfficerOpen-market sale−403$9.5094,821Form 4
13 May 2026Mano MichaelEVP, CLO&SecretaryGrant or award+700—94,664Form 4
13 May 2026Paulson Richard A.President and CEOGrant or award+4,920—271,950Form 4
13 May 2026Abate KristinChief Accounting OfficerGrant or award+121—23,854Form 4
13 May 2026Cheng Sohanya RoshanEVP & Chief Commercial OfficerGrant or award+947—108,264Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Karyopharm Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.